ORPHA:251899
Choroid plexus carcinoma
Publications
1,622
Trials
8
Interventional, condition-specific
Researchers
1,186
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Choroid plexus carcinoma is a rare and highly aggressive malignant type of choroid plexus tumor occurring almost exclusively in children, presenting with cerebrospinal fluid obstruction in the lateral ventricles (most common), the fourth and third ventricles or in multiple ventricles, leading to hydrocephalus and increased intracranial pressure, and manifesting with nausea, vomiting, abnormal eye movements, gait impairment, and enlarged head circumference.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016718
- MeSH:C562943
- UMLS:C0431109
- NCIT:C4715
Additional Mondo synonyms (6)
anaplastic choroid plexus papilloma · carcinoma of choroid plexus · carcinoma of the choroid plexus · carcinoma, choroid plexus, malignant · choroid plexus carcinoma · choroid plexus carcinoma (morphologic abnormality)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,622 matched papers (1,033 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
8 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
13
Drugs / clinical candidates · MONDO_0016718
- CARBOPLATIN·phase 3
- CISPLATIN·phase 3
- CYCLOPHOSPHAMIDE·phase 3
- ETOPOSIDE·phase 3
- METHOTREXATE·phase 3
- TEMOZOLOMIDE·phase 3
- THIOTEPA·phase 3
- VINCRISTINE·phase 3
- TOPOTECAN·phase 2
- VINBLASTINE·phase 2
- MELPHALAN·phase 1
- PERILLYL ALCOHOL·phase 1
- SINTILIMAB·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,622
1,622 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,622 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,033 in the last 10 years · low confidence
Phrase hits: 1,622 · MeSH hits: 45
Who's working on it?
1,186
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Gilbertson RJ7 papers · 2026
CRUK Cambridge Institute, , Li Ka Shing Centre, Robinson Way , ,
Papers in Europe PMC - 02Thomas C6 papers · 2026
Institute of Neuropathology, University Hospital Münster, Münster, Germany.
Papers in Europe PMC - 03Finlay JL5 papers · 2025
Pediatrics and Radiation Oncology, The Ohio State University College of Medicine, Columbus, OH, USA.
Papers in Europe PMC - 04Hasselblatt M5 papers · 2026
Institute of Neuropathology, University Hospital Münster, Münster, Germany.
Papers in Europe PMC - 05Patrizi A5 papers · 2025
Zentrum für Molekulare Biologie der Universität Heidelberg, DKFZ-ZMBH Alliance, Heidelberg, Germany.
Papers in Europe PMC - 06Cooper E4 papers · 2026
CRUK Cambridge Institute, , Li Ka Shing Centre, Robinson Way , ,
Papers in Europe PMC - 07Kratz CP4 papers · 2026
Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. kratz.christian@mh-hannover.de.
Papers in Europe PMC - 08Masih KE4 papers · 2026
CRUK Cambridge Institute, , Li Ka Shing Centre, Robinson Way , ,
Papers in Europe PMC - 09
- 10Guadix SW3 papers · 2025
Department of Neurological Surgery, Weill Cornell Medicine, New York, New York, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
8
interventional trials for this specific condition
8 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
8 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 91.5th percentile).
low confidence · 91.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
8 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04185038·RECRUITING·Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Not reviewed·Conditions: Central Nervous System Tumor · Diffuse Intrinsic Pontine Glioma · Diffuse Midline Glioma · Ependymoma·Matched via name + MeSH
- NCT06357377·NOT YET RECRUITING·A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Not reviewed·Conditions: Pediatric Tumor of CNS · Pediatric Tumor of Brain · Diffuse Midline Glioma, H3 K27M-Mutant · Pediatric Tumor of Brain Stem·Matched via name + MeSH
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03050268·RECRUITING·Familial Investigations of Childhood Cancer Predisposition
Not reviewed·Conditions: Acute Leukemia · Adenomatous Polyposis · Adrenocortical Carcinoma · AML·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Choroid plexus carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Choroid plexus carcinoma" OR "anaplastic choroid plexus papilloma" OR "carcinoma of choroid plexus" OR "carcinoma of the choroid plexus" OR "carcinoma, choroid plexus, malignant" OR "choroid plexus carcinoma (morphologic abnormality)"
MeSH descriptor terms unioned into the query: Choroid Plexus Carcinoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Choroid plexus carcinoma" OR "anaplastic choroid plexus papilloma" OR "carcinoma of choroid plexus" OR "carcinoma of the choroid plexus" OR "carcinoma, choroid plexus, malignant" OR "choroid plexus carcinoma (morphologic abnormality)"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 8 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1622) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T10:54:13.471Z
